vs
NEUROCRINE BIOSCIENCES INC（NBIX）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是NEUROCRINE BIOSCIENCES INC的1.8倍（$1.5B vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -3.1%，领先22.2%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -11.9%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 25.0%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
NBIX vs RXO — 直观对比
营收规模更大
RXO
是对方的1.8倍
$805.5M
营收增速更快
NBIX
高出40.2%
-11.9%
净利率更高
NBIX
高出22.2%
-3.1%
自由现金流更多
NBIX
多$395.0M
$-9.0M
两年增速更快
RXO
近两年复合增速
25.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.5B |
| 净利润 | $153.7M | $-46.0M |
| 毛利率 | 97.8% | — |
| 营业利润率 | 26.2% | -2.9% |
| 净利率 | 19.1% | -3.1% |
| 营收同比 | 28.3% | -11.9% |
| 净利润同比 | 49.1% | -84.0% |
| 每股收益（稀释后） | $1.49 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBIXRXO
| Q4 25 | $805.5M | $1.5B | ||
| Q3 25 | $794.9M | $1.4B | ||
| Q2 25 | $687.5M | $1.4B | ||
| Q1 25 | $572.6M | $1.4B | ||
| Q4 24 | $627.7M | $1.7B | ||
| Q3 24 | $622.1M | $1.0B | ||
| Q2 24 | $590.2M | $930.0M | ||
| Q1 24 | $515.3M | $913.0M |
净利润NBIXRXO
| Q4 25 | $153.7M | $-46.0M | ||
| Q3 25 | $209.5M | $-14.0M | ||
| Q2 25 | $107.5M | $-9.0M | ||
| Q1 25 | $7.9M | $-31.0M | ||
| Q4 24 | $103.1M | $-25.0M | ||
| Q3 24 | $129.8M | $-243.0M | ||
| Q2 24 | $65.0M | $-7.0M | ||
| Q1 24 | $43.4M | $-15.0M |
毛利率NBIXRXO
| Q4 25 | 97.8% | — | ||
| Q3 25 | 98.2% | — | ||
| Q2 25 | 98.4% | — | ||
| Q1 25 | 98.4% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 98.7% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.5% | — |
营业利润率NBIXRXO
| Q4 25 | 26.2% | -2.9% | ||
| Q3 25 | 30.1% | -0.5% | ||
| Q2 25 | 21.2% | — | ||
| Q1 25 | 4.1% | -2.1% | ||
| Q4 24 | 22.6% | -1.4% | ||
| Q3 24 | 29.5% | -1.9% | ||
| Q2 24 | 24.6% | — | ||
| Q1 24 | 19.3% | -1.3% |
净利率NBIXRXO
| Q4 25 | 19.1% | -3.1% | ||
| Q3 25 | 26.4% | -1.0% | ||
| Q2 25 | 15.6% | -0.6% | ||
| Q1 25 | 1.4% | -2.2% | ||
| Q4 24 | 16.4% | -1.5% | ||
| Q3 24 | 20.9% | -23.4% | ||
| Q2 24 | 11.0% | -0.8% | ||
| Q1 24 | 8.4% | -1.6% |
每股收益（稀释后）NBIXRXO
| Q4 25 | $1.49 | $-0.28 | ||
| Q3 25 | $2.04 | $-0.08 | ||
| Q2 25 | $1.06 | $-0.05 | ||
| Q1 25 | $0.08 | $-0.18 | ||
| Q4 24 | $1.00 | $-0.17 | ||
| Q3 24 | $1.24 | $-1.81 | ||
| Q2 24 | $0.63 | $-0.06 | ||
| Q1 24 | $0.42 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $3.3B | $1.5B |
| 总资产 | $4.6B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资NBIXRXO
| Q4 25 | $713.0M | $17.0M | ||
| Q3 25 | $340.2M | $25.0M | ||
| Q2 25 | $264.0M | $18.0M | ||
| Q1 25 | $194.1M | $16.0M | ||
| Q4 24 | $233.0M | $35.0M | ||
| Q3 24 | $349.1M | $55.0M | ||
| Q2 24 | $139.7M | $7.0M | ||
| Q1 24 | $396.3M | $7.0M |
总债务NBIXRXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益NBIXRXO
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | $3.0B | $1.6B | ||
| Q2 25 | $2.7B | $1.6B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.6B | $1.6B | ||
| Q3 24 | $2.7B | $1.7B | ||
| Q2 24 | $2.5B | $579.0M | ||
| Q1 24 | $2.4B | $582.0M |
总资产NBIXRXO
| Q4 25 | $4.6B | $3.3B | ||
| Q3 25 | $4.3B | $3.2B | ||
| Q2 25 | $3.9B | $3.2B | ||
| Q1 25 | $3.7B | $3.3B | ||
| Q4 24 | $3.7B | $3.4B | ||
| Q3 24 | $3.5B | $3.4B | ||
| Q2 24 | $3.3B | $1.8B | ||
| Q1 24 | $3.5B | $1.8B |
负债/权益比NBIXRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $-9.0M |
| 自由现金流率自由现金流/营收 | 47.9% | -0.6% |
| 资本支出强度资本支出/营收 | 0.3% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流NBIXRXO
| Q4 25 | $388.4M | $7.0M | ||
| Q3 25 | $227.5M | $23.0M | ||
| Q2 25 | $102.0M | $23.0M | ||
| Q1 25 | $64.8M | $-2.0M | ||
| Q4 24 | $242.5M | $-7.0M | ||
| Q3 24 | $158.0M | $-7.0M | ||
| Q2 24 | $64.6M | $-5.0M | ||
| Q1 24 | $130.3M | $7.0M |
自由现金流NBIXRXO
| Q4 25 | $386.0M | $-9.0M | ||
| Q3 25 | $214.3M | $9.0M | ||
| Q2 25 | $89.5M | $9.0M | ||
| Q1 25 | $54.1M | $-17.0M | ||
| Q4 24 | $235.2M | $-19.0M | ||
| Q3 24 | $149.9M | $-18.0M | ||
| Q2 24 | $53.0M | $-16.0M | ||
| Q1 24 | $119.1M | $-4.0M |
自由现金流率NBIXRXO
| Q4 25 | 47.9% | -0.6% | ||
| Q3 25 | 27.0% | 0.6% | ||
| Q2 25 | 13.0% | 0.6% | ||
| Q1 25 | 9.4% | -1.2% | ||
| Q4 24 | 37.5% | -1.1% | ||
| Q3 24 | 24.1% | -1.7% | ||
| Q2 24 | 9.0% | -1.7% | ||
| Q1 24 | 23.1% | -0.4% |
资本支出强度NBIXRXO
| Q4 25 | 0.3% | 1.1% | ||
| Q3 25 | 1.7% | 1.0% | ||
| Q2 25 | 1.8% | 1.0% | ||
| Q1 25 | 1.9% | 1.0% | ||
| Q4 24 | 1.2% | 0.7% | ||
| Q3 24 | 1.3% | 1.1% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 2.2% | 1.2% |
现金转化率NBIXRXO
| Q4 25 | 2.53× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
